Search the Newsreel

Certara, Inc. (CERT) Q1 2024 Earnings Report - Results, Call & Slides

Certara, Inc. (CERT) released its Q1 2024 earnings report, revealing an EPS of $1.75, missing the consensus estimate of $1.80 by -$0.05. However, the company's actual revenue of $1.69 billion exceeded the expected revenue of $1.64 billion, marking a 7.04% year-over-year growth. The earnings …

Protara Therapeutics Inc (TARA) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Protara Therapeutics Inc (TARA), detailing its volatility, financial risks, and investment risks. TARA has a risk assessment score of 3.34, ranking it 138 out of 386 in the Biotechnology & Medical Research industry, and exhibits a beta …

Form 4 Atara Biotherapeutics Inc For: 24 July By Investing.com

This article from Investing.com reports on a Form 4 filing for Atara Biotherapeutics Inc, referencing the date of July 24. The brief piece includes the stock symbol ATRA and notes a -3.30% change. It appears to be a standard financial markets update on insider …

Redmile adjusts Atara Biotherapeutics (ATRA) ownership after warrant exercises

Redmile Group, LLC has updated its ownership in Atara Biotherapeutics (ATRA) through an amended Schedule 13D/A filing, reflecting a beneficial ownership of 950,994 shares, or 9.9% of the outstanding common stock. This adjustment follows a cashless exercise of pre-funded warrants on July 16, 2026, …

Atara Biotherapeutics Inc (ATRA) Cash Flow

This article provides a detailed cash flow statement for Atara Biotherapeutics Inc (ATRA), covering numerous quarterly periods. It includes data on operating, investing, and financing cash flows, along with a free cash flow analysis. The page also offers definitions and FAQs regarding cash flow …

ATRA|Atara Biotherapeutics Inc|Price:8.089|Chg%:-0.081

Atara Biotherapeutics Inc (ATRA) is an allogeneic T-cell immunotherapy company focused on developing therapies for serious diseases using its Epstein-Barr virus (EBV) T-cell platform. The company's stock shows significant growth potential and is considered fairly valued within the Biotechnology & Medical Research industry, despite …

Avoiding Lag: Real-Time Signals in (ATRA) Movement

This article provides a real-time analysis of Atara Biotherapeutics Inc. (NASDAQ: ATRA) stock movement, highlighting weak sentiment across all horizons supporting a short bias. It details three AI-generated institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide investors. …

Price to sales forward of Atara Biotherapeutics, Inc. – NASDAQ:ATRA

This article provides the "Price to sales forward" financial metric for Atara Biotherapeutics, Inc. (NASDAQ: ATRA). It is a finance-related data point from TradingView, which aggregates market data from sources like ICE Data Services and FactSet. The page indicates no current trade activity for …

Anatara Lifesciences: Could Its Gut-Health Pipeline Put This Penny Stock Back on the Radar?

Technical Reactions to CERT Trends in Macro Strategies

This article provides a technical analysis of Certara Inc. (NASDAQ: CERT), highlighting near-term weak sentiment but mid-term strength within a broader long-term weak bias. It outlines institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis to guide potential …

Price to book forward of Atara Biotherapeutics Inc – SWB:AT20

This article provides financial data for Atara Biotherapeutics Inc (SWB:AT20) on the Stuttgart Stock Exchange, specifically focusing on its price to book forward ratio. It highlights that the market is currently closed with no trades. The content is primarily a data presentation with minimal …

Enterprise value to revenue forward of Atara Biotherapeutics Inc – SWB:AT20

This article provides financial information for Atara Biotherapeutics Inc (SWB:AT20), specifically focusing on its enterprise value to revenue forward. It notes that the market for AT20 was closed with no trades. The content also mentions that financial data is provided by ICE Data Services …

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT

NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. (“Certara” or the “Company”) (NASDAQ: CERT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether …

What date does Protara Therapeutics's (TARA) report Earnings - Earnings Calendar & Announcement

Should I buy Protara Therapeutics (TARA)

What Makes Protara Therapeutics (TARA) a New Buy Stock

How Certara’s NVIDIA AI Partnership Could Reshape CERT’s Long-Term Drug Development Narrative

Certara, Inc. announced a partnership with NVIDIA Corporation to integrate NVIDIA’s BioNeMo Agent Toolkit into Certara’s open, AI-first biosimulation platform. This collaboration aims to accelerate drug development workflows by combining scientific software, regulatory expertise, and proprietary datasets with agentic AI. The partnership reinforces Certara's …

Tara Chand Infralogistic Solutions approves all resolutions at 14th AGM

Certara files Form 3 for interim CFO Mohammed Faiz initial beneficial ownership statement

Certara's interim CFO, Mohammed Faiz, has filed a Form 3, disclosing his initial beneficial ownership in the company. The filing indicates direct ownership of 163,686 common shares and equity awards covering an additional 28,164 shares. This information was generated by Public Technologies (PUBT) using …

Certara (CERT) interim CFO discloses stock, RSU and PSU holdings

Certara, Inc.'s interim CFO, Mohammed Faiz, has filed an initial ownership report disclosing a direct holding of 163,686 shares of Common Stock. The report also details his equity awards, including 8,544 Performance Stock Units (PSUs) and Restricted Stock Units (RSUs) covering 13,290 and 6,330 …

Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Atara Biotherapeutics, Inc. (NASDAQ: ATRA) concerning potential corporate wrongdoing by its officers and/or directors. The firm is encouraging investors who purchased Atara securities prior to May 20, 2024, and still hold them, to contact …

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. (NASDAQ: ATRA) securities. The investigation focuses on whether Atara and its officers engaged in corporate wrongdoing, particularly for investors who purchased shares before May 20, 2024. The …

Ekspansi ke Vietnam, Wahana Interfood (COCO) Bakal Tebus 99,99 Persen Saham Momogi Group

Price to sales forward of PT Abadi Nusantara Hijau Investama Tbk – IDX:PACK

Certara to report Q2 2026 financial results on August 4

Certara, Inc. announced it will release its second-quarter 2026 financial results before market open on August 4, 2026, followed by a conference call at 8:30 AM ET. The company, a specialist in model-informed drug development, requires investors to register online in advance to participate …

Certara sets Aug. 4 call to discuss second-quarter results

Certara (Nasdaq: CERT) announced it will release its second-quarter 2026 financial results before market open on Tuesday, August 4, 2026. Company management will host a conference call to discuss the results at 8:30 AM ET, and investors are required to register online in advance. …

Anatara Lifesciences (ASX:ANR) Holds Steady: Is the Market Overlooking Its Emerging Healthcare Opportunity?

Tara Chand Infralogistic Solutions Limited (NSE:TARACHAND) Looks Like A Good Stock, And It's Going Ex-Dividend Soon

Tara Chand Infralogistic completes Rs 40.59 Cr capex in Q1FY27

Apa Dampak Agunan 50 Persen Citra Nusantara (CGAS) terhadap Kinerja Keuangannya?

TOWR Forecast — Price Target — Prediction for 2027

Price to earnings forward of PT Nusantara Sawit Sejahtera Tbk – IDX:NSSS

Tara Chand Stock Jumps 16% on ₹83.14 Cr FY26 Capex Finish

Dharma Satya Nusantara (DSNG): Company Profile, Stock Price, News, Rankings

Coal sales decline, BIPI swings to loss in first quarter

Tarapur Transformers reports FY26 loss, auditors flag going concern